Clinical Features of Metastatic Cohort
| Parameter | Data |
|---|---|
| Sex | |
| Male | 7 |
| Female | 1 |
| Age | 72.5 (68–87) |
| Primary site of disease | |
| Bladder | 6 |
| Upper tract | 2 |
| Race | |
| White | 3 |
| Hispanic | 1 |
| Asian | 4 |
| Prior definitive treatment | |
| Nephroureterectomy | 2 |
| Cystectomy | 5 |
| Systemic treatments before/at time of scan | |
| Chemotherapy | 8 |
| Immune checkpoint inhibitors | 7 |
| Antibody–drug conjugate | 4 |
| Histologic subtype | |
| Urothelium-predominant | 8 |
| Variant histology | 0 |
| Metastatic site | |
| Lymph node only | 3 |
| Any visceral disease (not lymph nodes only) | 4 |
| Bones | 4 |
| Liver | 1 |
| Concurrent 18F-FDG PET available | 3 |
Qualitative data are number (n = 8 patients total); continuous data are median and range.